Clinical Trials Logo
  1. Home
  2. Mild Cognitive Impairment (MCI)
  3. NCT00544791

The Effect of Melatonin on Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment — MCI  

Mild Cognitive Impairment (MCI) Clinical Trial

Official title:
The Effect of Melatonin on Memory and Other Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment (MCI): A Placebo- Controlled Study.

Clinical Trial Summary

Recent studies have described the role of melatonin as a sleep regulator and as an anti- oxidative neuroprotective agent in improving sleep quality and delaying cognitive decline in Alzheimer's disease (AD).

In accordance with this data, our hypothesis is that melatonin will delay the cognitive decline in Mild Cognitive Impairment (MCI) patients and reduce the conversion rate from MCI to AD.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00544791
Study type Interventional
Source Assaf-Harofeh Medical Center
Contact Michael khaigrekht, MD
Phone 972-8-9779823
Email khaigrekhtm@asaf.health.gov.il
Status Recruiting
Phase Phase 2
Start date October 2007
Completion date October 2010
View Details
See also
  Status Clinical Trial Phase
Completed NCT00934531 - Donepezil and the Risk of Falls in Seniors With Cognitive Impairment N/A
Withdrawn NCT05033912 - A Study of CST-2032 in Subjects With Cognitive Impairment Phase 1
Recruiting NCT02854033 - Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Completed NCT01902004 - Brain Aging and Treatment Response in Geriatric Depression Phase 4
Completed NCT01212692 - Effects of Mental Stimulation in Patients With Mild Cognitive Impairment Phase 2
Withdrawn NCT04055532 - Biomarkers in Neurodegenerative Diseases
Terminated NCT02180529 - The Effects of Methylphenidate on the Cognitive Function of Older People With Mild Cognitive Impairment N/A
Completed NCT05108922 - A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4) Phase 3
Recruiting NCT05865340 - To Exam the Efficacy of Oral Health and Mediterranean Diet Interventions in Preventing Cognitive Decline Among Older Adults With Mild Cognitive Impairment N/A
Completed NCT02110043 - Modulation of Visual-Spatial Learning in Patients With Mild Cognitive Impairment (MCI) by tDCS N/A
Completed NCT01383161 - 18-Month Study of Memory Effects of Curcumin Phase 2
Completed NCT01299766 - Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment Phase 3
Withdrawn NCT05321498 - Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation Phase 2
Completed NCT04748666 - PST for Care Partners of Adults With Alzheimer's and Alzheimer'S-related Dementia N/A
Recruiting NCT03138018 - Aging Stereotypes and Prodromal Alzheimer's Disease N/A
Withdrawn NCT01891383 - Clinical Characteristics of Dementias That Occur Remotely After Traumatic Brain Injury in Retired Military Personnel
Recruiting NCT03448055 - Nutritional Intervention With the Dietary Supplement, Immunocal® in MCI Patients: Promotion of Brain Health N/A
Completed NCT01231971 - Alzheimer's Disease Neuroimaging Initiative 2
Completed NCT01044758 - Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI) Phase 2
Recruiting NCT05014893 - Neural Mechanisms of Cognitive Assessment and Rehabilitation for Cognitive Decline N/A